LILRB1 and lymphoma: In combination with a CD20 antibody (i.e. rituximab or obinutuzumab) for FcγR engagement and an Fc-silent CD47 antibody to inhibit SIRPα signaling, LILRB1 antibody blockade further enhanced the phagocytic uptake of lymphoma cells by macrophages in vitro compared to the combination of CD20 antibodies and CD47 blockade only.